Literature DB >> 15621990

Prerandomization Surgical Training for the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-32 trial: a randomized phase III clinical trial to compare sentinel node resection to conventional axillary dissection in clinically node-negative breast cancer.

Seth P Harlow1, David N Krag, Thomas B Julian, Takamaru Ashikaga, Donald L Weaver, Sheldon A Feldman, V Suzanne Klimberg, Roberto Kusminsky, Frederick L Moffat, R Dirk Noyes, Peter D Beitsch.   

Abstract

OBJECTIVE: To train surgeons in a standardized technique of sentinel lymph node biopsy and to prepare them for the requirements of a prospective randomized surgical trial. SUMMARY BACKGROUND DATA: The NSABP B32 trial opened to accrual in May 1999. A significant component of this trial was a prerandomization training phase of surgeons performed by a group of core surgical trainers. The goals of this training phase were to expeditiously instruct surgeons in a standardized technique of sentinel lymph node biopsy and to educate those same surgeons in complete and accurate data collection and source documentation for the trial.
METHODS: This study is a description of the training data collected in a prospective fashion for the training component for surgeon entry into the B32 trial, evaluating the effectiveness of the training program in regards to surgical outcomes and protocol compliance.
RESULTS: Two hundred twenty-six registered surgeons underwent site visit training by a core surgical trainer and 187 completed training and were approved to randomize patients on the trial. The results of 815 training (nontrial) cases demonstrated a technical success rate for identifying sentinel nodes at 96.2% with a false negative rate of 6.7%. A protocol compliance analysis, which included the evaluation of 94 separate fields, showed mean protocol compliance of 98.6% for procedural fields, 95.5% for source documentation fields and 95.0% for data entry fields.
CONCLUSIONS: This training and quality control program has resulted in a large number of surgeons capable of performing sentinel lymph node biopsy in a standardized fashion with a high degree of protocol compliance and pathologic accuracy. This will ensure optimal results for procedures performed on the randomized phase of the trial.

Entities:  

Mesh:

Year:  2005        PMID: 15621990      PMCID: PMC1356845          DOI: 10.1097/01.sla.0000149429.39656.94

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  16 in total

Review 1.  Surgical trials in oncology. the importance of quality control in the TME trial.

Authors:  E Klein Kranenbarg; C J H van de Velde
Journal:  Eur J Cancer       Date:  2002-05       Impact factor: 9.162

2.  Morbidity and mortality after D2 gastrectomy for gastric cancer: results of the Italian Gastric Cancer Study Group prospective multicenter surgical study.

Authors:  M Degiuli; M Sasako; A Ponti; T Soldati; F Danese; F Calvo
Journal:  J Clin Oncol       Date:  1998-04       Impact factor: 44.544

3.  North American Symptomatic Carotid Endarterectomy Trial. Methods, patient characteristics, and progress.

Authors: 
Journal:  Stroke       Date:  1991-06       Impact factor: 7.914

4.  Sentinel node biopsy in breast cancer: ALMANAC trial.

Authors:  D Clarke; N I Khonji; R E Mansel
Journal:  World J Surg       Date:  2001-05-14       Impact factor: 3.352

5.  Surgical treatment variation in a prospective, randomized trial of chemoradiotherapy in gastric cancer: the effect of undertreatment.

Authors:  Scott A Hundahl; John S Macdonald; Jacqueline Benedetti; Thomas Fitzsimmons
Journal:  Ann Surg Oncol       Date:  2002-04       Impact factor: 5.344

6.  Therapeutic options and results for the management of minimally invasive carcinoma of the breast: influence of axillary dissection for treatment of T1a and T1b lesions.

Authors:  R E White; M P Vezeridis; M Konstadoulakis; B F Cole; H J Wanebo; K I Bland
Journal:  J Am Coll Surg       Date:  1996-12       Impact factor: 6.113

7.  Surgical quality control in an international randomized clinical trial.

Authors:  H Schraffordt Koops
Journal:  Eur J Surg Oncol       Date:  1992-12       Impact factor: 4.424

8.  Surgical results: a justification of the surgeon selection process for the ACAS trial. The ACAS Investigators.

Authors:  W S Moore; B Young; W H Baker; J T Robertson; J F Toole; C L Vescera; V J Howard
Journal:  J Vasc Surg       Date:  1996-02       Impact factor: 4.268

9.  The sentinel node in breast cancer--a multicenter validation study.

Authors:  D Krag; D Weaver; T Ashikaga; F Moffat; V S Klimberg; C Shriver; S Feldman; R Kusminsky; M Gadd; J Kuhn; S Harlow; P Beitsch
Journal:  N Engl J Med       Date:  1998-10-01       Impact factor: 91.245

10.  Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group.

Authors:  A Cuschieri; S Weeden; J Fielding; J Bancewicz; J Craven; V Joypaul; M Sydes; P Fayers
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640

View more
  39 in total

1.  Lymphatic mapping and sentinel lymph node biopsy for breast cancer patients.

Authors:  Lisa A Newman
Journal:  J Oncol Pract       Date:  2005-11       Impact factor: 3.840

2.  A declining rate of completion axillary dissection in sentinel lymph node-positive breast cancer patients is associated with the use of a multivariate nomogram.

Authors:  Julia Park; Jane V Fey; Arpana M Naik; Patrick I Borgen; Kimberly J Van Zee; Hiram S Cody
Journal:  Ann Surg       Date:  2007-03       Impact factor: 12.969

3.  The landmark surgical trials of the National Surgical Adjuvant Breast and Bowel Project.

Authors:  D Lawrence Wickerham; Joseph P Costantino; Eleftherios P Mamounas; Thomas B Julian
Journal:  World J Surg       Date:  2006-07       Impact factor: 3.352

4.  Canadian Association of General Surgeons and American College of Surgeons Evidence-Based Reviews in Surgery. 27. Quality-of-life outcomes with sentinel node biopsy versus standard axillary treatment in patients with operable breast cancer. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial.

Authors:  Steve Latosinsky; Kelly Dabbs; Frederick Moffat
Journal:  Can J Surg       Date:  2008-12       Impact factor: 2.089

Review 5.  Trends and controversies in multidisciplinary care of the patient with breast cancer.

Authors:  Laura S Dominici; Monica Morrow; Elizabeth Mittendorf; Jennifer Bellon; Tari A King
Journal:  Curr Probl Surg       Date:  2016-11-29       Impact factor: 1.909

6.  Patient-reported outcomes in sentinel node-negative adjuvant breast cancer patients receiving sentinel-node biopsy or axillary dissection: National Surgical Adjuvant Breast and Bowel Project phase III protocol B-32.

Authors:  Stephanie R Land; Jacek A Kopec; Thomas B Julian; Ann M Brown; Stewart J Anderson; David N Krag; Nicholas J Christian; Joseph P Costantino; Norman Wolmark; Patricia A Ganz
Journal:  J Clin Oncol       Date:  2010-08-02       Impact factor: 44.544

7.  Real-time intraoperative detection of breast cancer axillary lymph node metastases using a green fluorescent protein-expressing herpes virus.

Authors:  David P Eisenberg; Prasad S Adusumilli; Karen J Hendershott; Sun Chung; Zhenkun Yu; Mei-Ki Chan; Michael Hezel; Richard J Wong; Yuman Fong
Journal:  Ann Surg       Date:  2006-06       Impact factor: 12.969

8.  Prediction of involvement of sentinel and nonsentinel lymph nodes in a Canadian population with breast cancer.

Authors:  Ravi Ramjeesingh; May Lynn Quan; Sandra Gardner; Claire M B Holloway
Journal:  Can J Surg       Date:  2009-02       Impact factor: 2.089

9.  Identification of Sentinel Lymph Nodes Using Contrast-Enhanced Ultrasound in Breast Cancer.

Authors:  Naresh Kumar Saidha; Rohit Aggarwal; Arijit Sen
Journal:  Indian J Surg Oncol       Date:  2017-06-17

10.  Surgeon training, protocol compliance, and technical outcomes from breast cancer sentinel lymph node randomized trial.

Authors:  David N Krag; Takamaru Ashikaga; Seth P Harlow; Joan M Skelly; Thomas B Julian; Ann M Brown; Donald L Weaver; Norman Wolmark
Journal:  J Natl Cancer Inst       Date:  2009-08-24       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.